Mahantesh Sabarad, deputy vice president (research) at SBICap Securities, says Granules India, which was earlier into manufacturing of active pharmaceutical ingredients, is now getting into abbreviated new drug application filings. He expects a topline growth of more than 20 per cent for the company.
